… targets in clinical treatment. But the EGFR tyrosine kinase inhibitors (TKI)-resistance is
becoming a … pathway contributed to Erlotinib resistance in EGFR-mutant NSCLC cell line H1650. …

… histologic features of adenocarcinoma, squamouscell carcinoma or … Further adjustments
were made based on the specific … in previously treated nonsmall cell lung cancer (INTEREST): …

… been used to treat lung cancer and prevent lung cancer metastasis for … non-small cell lung
cancer cell lines with FZKA concentration… drugs that are more specific to tumor characteristics. …

… to the characteristics of tumor genetic mutations, tumor … produced by receiver operating
characteristic (ROC) curves. … We acknowledge and thank all the medical staff who treated …

… smooth muscle cells treated with heparin with those treated with … and in lung cancer.102,
103 In breast carcinoma, CCN2 … in the human breast cancer cell line MDA MB231,106, 108 …

… lung cancer, NSCLC）的靶向治疗中，伴有EGFR基因突变的患者使用EGFR酪氨酸激酶抑制剂
（EGFR-tyrosine kinase inhibitors… TKIs-treated patients eventually suffer drug resistant after 10-…

… However, due to the unique features of NSCLC with epidermal growth factor receptor (… EGFR
mutations that may benefit from ICIs treatment, and analyzes how decisions can be made in …

… contribution to personalized treatment of lung cancer in the future. … profiles of a highly
metastatic lung cancer cell line, NCI-H460-… tobacco exposure and clinicopathologic features. Clin …

… , the treatment for lung adenocarcinoma has made a great … , the incidence of epidermal growth
factor receptor (EGFR) gene … a new target for treatment of squamous cell lung cancer. This …

… standard treatment for advanced non-small cell lung cancer (… inherent resistance to available
EGFR tyrosine kinase inhibitors (… of EGFR and its influence on EGFR inhibitor sensitivity, as …